Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Type: Poster Session

Time: Monday June 5, 8:00 AM to 11:30 AM

Location: Hall A

The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.

Sub-category:
Multiple Myeloma

Category:
Hematologic Malignancies—Plasma Cell Dyscrasia

Meeting:
2017 ASCO Annual Meeting

Abstract No:
8032

Poster Board Number:
Poster Session (Board #358)

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 8032)

Author(s): Wilson I. Gonsalves, S. Vincent Rajkumar, Angela Dispenzieri, Martha Lacy, Francis Buadi, David Dingli, Ronald S. Go, Prashant Kapoor, Suzanne R. Hayman, John Anthony Lust, Nelson Leung, Stephen J. Russell, Steven R. Zeldenrust, Yi Lin, Yi Lisa Hwa, Taxiarchis Kourelis, Robert A. Kyle, Morie A. Gertz, Shaji Kumar; Division of Hematology, Mayo Clinic, Rochester, MN; Mayo Clinic, Rochester, MN

Abstract Disclosures

Abstract:

Background: Human adipocytes can contribute directly to the in vitro growth and progression of multiple myeloma (MM) cell lines. Clinically, an elevated body mass index (BMI) has been associated with an increased risk of MGUS and a shorter time to progression (TTP) of MGUS to MM. However, the impact of BMI on the risk of early progression to MM from a more advanced plasma cell disorder such as smoldering MM (SMM) remains unknown. Methods: This study included patients (pts) with a known or new diagnosis of SMM evaluated at the Mayo Clinic, Rochester from January 2000-December 2010. Pts were classified based on their BMI as: normal (< 25) and elevated (>/= 25) BMI. Progression to symptomatic MM was defined by the development of hypercalcemia, renal insufficiency, anemia or lytic bone lesions. Results: There were 306 pts with a diagnosis of SMM who were included in this analysis. The median follow up was 106 months. There were 203 (66%) pts who progressed to symptomatic MM at last follow up. The median BMI of the group was 27.5 (Range: 17.2 – 56.4). There were 228 (75%) pts with an elevated BMI. There were 76 (28%) pts who had myeloma defining events (MDEs) such as a serum free light chain ratio > 100 or > 60% clonal bone marrow plasma cells at initial evaluation. MDEs were present in 17% and 33% of pts with a normal and elevated BMI respectively (P = 0.011). The median TTP of SMM to MM in pts with a normal and elevated BMI was 64 and 36 months respectively (P = 0.0006). The 2-year progression rate of SMM to symptomatic MM in pts with a normal and elevated BMI was 16% and 42% respectively (P < 0.0001). Upon limiting the analysis to only SMM pts without MDEs at initial evaluation (N =187), the 2-year progression rate to symptomatic MM with a normal and elevated BMI was 15% and 33% respectively (P = 0.013). In a multivariable model, only elevated BMI (P = 0.004) and increasing clonal bone marrow plasma cells (P = 0.001) was statistically significant in predicting for a 2-year progression to MM. Conclusions: SMM pts with an elevated BMI appear to have a higher risk of early progression to MM than those with a normal BMI. This study provides evidence of a potentially modifiable risk factor for the progression of SMM to MM and warrants confirmation in larger studies.

 
Other Abstracts in this Sub-Category:

 

1. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.

Meeting: 2017 ASCO Annual Meeting Abstract No: 8000 First Author: Andrzej J. Jakubowiak
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

2. Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.

Meeting: 2017 ASCO Annual Meeting Abstract No: 8001 First Author: Stefan Knop
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

3. An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.

Meeting: 2017 ASCO Annual Meeting Abstract No: 8002 First Author: Jacob Laubach
Category: Hematologic Malignancies—Plasma Cell Dyscrasia - Multiple Myeloma

 

More...